- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 13th, 2007
Personalized-medicine startup Nanosphere filed for a $100 million IPO Monday, but an analyst said the move could be a prelude to a merger with one of its larger rivals.
Nanosphere, based in Northbrook, Illinois, makes a system to perform molecular diagnostic tests. Earlier this year Nanosphere applied for U.S. Food and Drug Administration approval of tests to gauge a person's risk of blood clots and how a patient metabolizes the anti-blood clot medicine warfarin, sold under the brand name Coumadin.
The company also is developing tests for cancer, cystic fibrosis gene mutation, herpes viral infection, and cardiovascular disease risk and diagnosis.
|Related News Press|
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Nanoscale Trojan horses treat inflammation May 24th, 2016
Programmable materials find strength in molecular repetition May 23rd, 2016
Deep Space Industries and SFL selected to provide satellites for HawkEye 360ís Pathfinder mission: The privately-funded space-based global wireless signal monitoring system will be developed by Deep Space Industries and UTIAS Space Flight Laboratory May 26th, 2016
The next generation of carbon monoxide nanosensors May 26th, 2016
Gigantic ultrafast spin currents: Scientists from TU Wien (Vienna) are proposing a new method for creating extremely strong spin currents. They are essential for spintronics, a technology that could replace today's electronics May 25th, 2016